Loading
Ultra-sensitive whole-body scanners can measure exactly where a radioactive drug goes at tiny tracer doses, allowing each patient's therapeutic dose to be tailored.
Radioligand therapy is given at fixed activity despite wide variation in tumour and kidney dose, so this idea uses ultra-sensitive total-body PET with 44Sc- or 89Zr-labelled analogues to measure each patient's pharmacokinetics before treatment and tailor the therapeutic dose. Dosimetry-guided prescription of 177Lu-PSMA is expected to raise tumour absorbed dose and response without exceeding kidney and marrow limits. Personalised dosimetry is established in radioiodine and SIRT, and total-body scanners from United Imaging and Siemens Healthineers remove the imaging-time and dose barriers. The test is a randomised trial of dosimetry-guided versus fixed-dose Pluvicto in prostate cancer with PSA50 and rPFS endpoints. At early-clinical maturity it addresses the bottleneck Wrong doses.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer, PSMAddition, Dosimetry.
Shares PSMAfore, VISION, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
Shares United Imaging, SPECT & bone scan, Siemens Healthineers, PET/CT.
Shares PSMAfore, VISION, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
Shares United Imaging, Dosimetry, Siemens Healthineers, PET/CT.
Shares PSMAfore, Dosimetry, VISION, Lutetium-177 vipivotide tetraxetan.
Shares Qualify PSMA PET tumour volume as a validated imaging biomarker, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMAfore, Dosimetry, VISION, Lutetium-177 vipivotide tetraxetan.